Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.
Smyth
J F
JF
Department of Clinical Oncology, Western General Hospital, Edinburgh, UK.
Hardcastle
J D
JD
Denton
G
G
Alderson
D
D
Grace
R H
RH
Mansi
J L
JL
Yosef
H M
HM
Nordle
O
O
Lauri
H
H
Wählby
S
S
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D011788:Quality of Life; D012044:Regression Analysis; D015996:Survival Rate; D013654:Taurine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017211:Treatment Failure
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D013654:Taurine; C052991:1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea; D005472:Fluorouracil